The combined expression of Semaphorin4D and PlexinB1 predicts disease recurrence in colorectal cancer.
The combined expression of Semaphorin4D and PlexinB1 predicts disease recurrence in colorectal cancer.
复制标题
DOI：
10.1186/s12885-016-2577-6
复制
发表时间：
2016-07-25
期刊：
影响因子：
3.8
通讯作者：
Hirakawa K
中科院分区：
文献类型：
--
作者：
Ikeya T;Maeda K;Nagahara H;Shibutani M;Iseki Y;Hirakawa K
与Sema 4D和丛蛋白B1的结合诱导结直肠癌（CRC）中的血管生成和侵袭性生长。Semaphorin 4D（Sema 4D）和PlexinB 1的表达与多种恶性肿瘤患者的预后有关。然而，Sema 4D和PlexinB 1的表达与结直肠癌患者的无复发生存率之间的相关性仍存在争议。研究人群包括接受结直肠癌手术的患者（n = 226）。采用免疫组化法检测I、II、III期结肠癌组织中Sema 4D和PlexinB 1的表达。结直肠癌组织标本的免疫组化染色显示，95例（42%）和105例（46.4%）标本中Sema 4D和PlexinB 1阳性。Sema 4D和PlexinB 1的表达分别与肿瘤的分期、浸润深度、淋巴结转移、淋巴管浸润和静脉浸润有关。63例患者（27.9%）同时表达Sema 4D和丛蛋白B1。Sema 4D和PlexinB 1的阳性表达是影响生存率的独立危险因素（HR 1.079，CI 1.013-2.868; P = 0.044）。因此，免疫组化检测Sema 4D和PlexinB 1蛋白的组合可用于预测CRC患者的疾病复发。
Binding to Sema4D and PlexinB1 induce angiogenesis and invasive growth in colorectal cancer (CRC). The expression of Semaphorin4D (Sema4D) and PlexinB1 has been shown to be related to the prognosis of patients with various malignancies. However, the correlation between the expression of Sema4D and PlexinB1 and the relapse-free survival in patients with colorectal cancer remains controversial. The study population included patients who underwent surgery for colorectal cancer (n = 226). The expression of Sema4D and PlexinB1 were analyzed by immunohistochemistry in tissue of stage I, II, and III colon cancers. The immunohistochemical staining of colorectal cancer tissue specimens revealed that 95 (42 %) and 105 (46.4 %) of the specimens were positive for Sema4D and PlexinB1. The expression of Sema4D and PlexinB1 respectively were both found to be significantly related to stage, depth of tumor invasion, lymph node metastasis, lymphatic invasion, and venous invasion, respectively. Sixty-three patients (27.9 %) expressed both Sema4D and PlexinB1. The positive expression of both Sema4D and PlexinB1 was found to be an independent risk factor for a worse survival (HR 1.079, CI 1.013–2.868; P = 0.044). The combination of Sema4D and PlexinB1 protein detected by immunohistochemistry was therefore useful for predicting disease recurrence in CRC patients.